Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial
Some men with PSA <3 ng/ml harbor aggressive PCa with a substantial risk of recurrence after upfront curative treatment. Risk predictive blood tests, such as Stockholm3, used at lower PSA thresholds, can identify these men, while few clinically important cancers are missed when biopsy is deferred with PSA ≥3 ng/ml but low Stockholm3 scores.
Authors
- Peter N. Wiklund (ORCID: https://orcid.org/0000-0001-6497-4697)
- Ugo Giovanni Falagario (ORCID: https://orcid.org/0000-0002-1152-3005)
- Hari T. Vigneswaran (ORCID: https://orcid.org/0000-0001-9703-2655)
- Chiara Micoli (ORCID: https://orcid.org/0009-0001-6830-6255)
- Derya Tilki (ORCID: https://orcid.org/0000-0001-7033-1380)
- Axel Møller (ORCID: https://orcid.org/0000-0003-4532-2532)
- Markus Aly (ORCID: https://orcid.org/0000-0002-7602-9198)
- Olof Akre (ORCID: https://orcid.org/0000-0002-3750-3029)
- Scott E. Eggener (ORCID: https://orcid.org/0000-0001-6677-2503)
- Thorgerdur Palsdottir (ORCID: https://orcid.org/0000-0003-3491-3986)
- Daniel Wei Lin (ORCID: https://orcid.org/0000-0002-2135-1534)
- Martin Eklund (ORCID: https://orcid.org/0000-0001-5032-5266)
- Lars Egevad (ORCID: https://orcid.org/0000-0001-8531-222X)
- Matthew R. Cooperberg (ORCID: https://orcid.org/0000-0003-4339-6685)
- Tobias Nordström
- Henrik Grönberg
Institutions
- Universität Hamburg (DE)
- University of California, San Francisco (US)
- Karolinska Institutet (SE)
- University of Chicago (US)
- Fred Hutch Cancer Center (US)
- University Medical Center Hamburg-Eppendorf (DE)
- Martini-Klinik (DE)
Publication Details
- Journal
- European Urology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1016/j.eururo.2025.10.001
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00